Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01456689 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT01456689 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT01456689, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).
Interventions
- DRUG midazolam
- DRUG LGH447
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2012-04-25 |
| Est. Completion | 2019-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01456689
The ClinicalTrials.gov registry entry for NCT01456689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which midazolam is the first listed.
NCT01456689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01456689 about?
NCT01456689 is a clinical study titled "A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma". The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).
What is the current status of trial NCT01456689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2012-04-25. Estimated completion is 2019-06-05.
What interventions are being tested in trial NCT01456689?
The interventions under investigation include: midazolam (DRUG), LGH447 (DRUG).
Who is sponsoring clinical trial NCT01456689?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.